|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-4-25
|
|
pubmed:abstractText |
Gemcitabine is widely accepted as the first-line agent for advanced pancreatic cancer. The antitumor cell activity of gemcitabine is higher when administered after 5-fluorouracil (5-FU) rather than before 5-FU in an in vitro study. The present study was conducted to define the maximum tolerated dose and dose-limiting toxicity associated with an oral fluoropyrimidine prodrug that combines uracil and tegafur (UFT), given prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0009-3157
|
|
pubmed:author |
pubmed-author:FujiiTsuneshiT,
pubmed-author:HabiroAtsuyaA,
pubmed-author:IzawaTsutomuT,
pubmed-author:KohgoYutakaY,
pubmed-author:KoizumiKazuyaK,
pubmed-author:MizukamiYusukeY,
pubmed-author:NakanoYasuhiroY,
pubmed-author:OkumuraToshikatsuT,
pubmed-author:OsanaiManabuM,
pubmed-author:TannoSatoshiS,
pubmed-author:YanagawaNobuyukiN
|
|
pubmed:copyrightInfo |
Copyright 2006 S. Karger AG, Basel.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
98-102
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16567941-Administration, Oral,
pubmed-meshheading:16567941-Aged,
pubmed-meshheading:16567941-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16567941-Deoxycytidine,
pubmed-meshheading:16567941-Dose-Response Relationship, Drug,
pubmed-meshheading:16567941-Drug Administration Schedule,
pubmed-meshheading:16567941-Female,
pubmed-meshheading:16567941-Humans,
pubmed-meshheading:16567941-Male,
pubmed-meshheading:16567941-Maximum Tolerated Dose,
pubmed-meshheading:16567941-Middle Aged,
pubmed-meshheading:16567941-Pancreatic Neoplasms,
pubmed-meshheading:16567941-Prodrugs,
pubmed-meshheading:16567941-Tegafur,
pubmed-meshheading:16567941-Uracil
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer.
|
|
pubmed:affiliation |
Third Department of Internal Medicine, Asahikawa Medical College, Asahikawa, Japan. tanno1se@asahikawa-med.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I
|
